Meiyu Dong, Ph.D.
Affiliations: | 2009 | University of Florida, Gainesville, Gainesville, FL, United States |
Area:
Pharmacology, OncologyGoogle:
"Meiyu Dong"Parents
Sign in to add mentor| Dietmar W. Siemann | grad student | 2009 | UF Gainesville | |
| (Targeting tumor metastasis---SRC inhibition.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dong M, Bi J, Liu X, et al. (2016) Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report. Medicine. 95: e4368 |
| Zhang W, Bao L, Yang S, et al. (2016) Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells. Oncotarget |
| Wang Y, Cheng Q, Liu J, et al. (2016) Leukemia Stem Cell-Released Microvesicles Promote the Survival and Migration of Myeloid Leukemia Cells and These Effects Can Be Inhibited by MicroRNA34a Overexpression. Stem Cells International. 2016: 9313425 |
| Sheng W, Dong M, Chen C, et al. (2016) Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein. Oncotarget |
| Dong MH, Zhang Q, Wang YY, et al. (2016) Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway. Experimental and Therapeutic Medicine. 11: 1475-1480 |
| Siemann DW, Dong M, Pampo C, et al. (2012) Src-signaling interference impairs the dissemination of blood-borne tumor cells. Cell and Tissue Research. 349: 541-50 |
| Dong M, Rice L, Lepler S, et al. (2010) Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. Anticancer Research. 30: 4405-13 |
| Siemann DW, Dong M. (2009) Abstract B107: Targeting metastatic tumor cell functions by Src signaling interference using the small molecule Src inhibitor, saracatinib (AZD0530) Molecular Cancer Therapeutics. 8 |